导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.98% | 1031/4773 |
| 近一周 | -1.99% | 1030/5462 |
| 近一月 | -4.41% | 2448/5421 |
| 近一季 | -9.03% | 3072/5209 |
| 近半年 | -1.32% | 1553/4920 |
| 近一年 | 9.23% | 1111/4366 |
| 近两年 | 54.70% | 1350/2954 |
| 近三年 | 21.15% | 1427/2253 |
| 成立以来 | 110.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.60% 693/4961 |
15.33% 1681/5312 |
- - |
- - |
| 2025 | 20.90% 2072/4813 |
0.09% 1980/3635 |
4.23% 826/4076 |
14.11% 2947/4524 |
1.55% 1338/4813 |
| 2024 | 3.46% 1927/3463 |
-3.17% 1476/2808 |
-1.21% 982/3014 |
11.68% 2478/3129 |
-3.17% 2278/3463 |
| 2023 | -4.43% 678/2656 |
5.41% 788/2280 |
-2.62% 623/2385 |
0.80% 340/2515 |
-7.64% 2184/2655 |
| 2022 | -17.81% 633/2207 |
-15.97% 1090/1919 |
8.67% 339/2016 |
-13.77% 971/2113 |
4.38% 554/2208 |
| 2021 | -7.11% 1028/1822 |
-4.76% 885/1255 |
6.40% 754/1330 |
-8.72% 1151/1466 |
0.42% 1115/1822 |
| 2020 | 28.29% 564/1250 |
-11.78% 853/1028 |
12.91% 661/1067 |
13.47% 317/1164 |
13.50% 356/1184 |
| 2019 | 28.13% 524/1092 |
24.10% 531/754 |
0.81% 156/804 |
-2.58% 706/850 |
5.13% 746/918 |
| 2018 | -27.67% 427/834 |
- - |
- - |
- - |
-13.98% 567/691 |
| 2017 | 27.12% 93/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.92% 271/605 |
- - |
- - |
- - |
- - |
| 2015 | 2.39% 237/575 |
- - |
- - |
- - |
- - |
| 2014 | 46.14% 102/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国金300指数增强A VS. 长安沪深300非周期A(740101) |